Japan Approves Insurance Coverage For Three Diagnostics
This article was originally published in PharmAsia News
The Central Social Medical Insurance Agency (Chuikyo) April 21 approved insurance coverage for three diagnostic items. The council approved price listing for MESACUP anti-RNA polymerase III test for systemic scleroderma at ¥1,700, citing a high sensitivity in systemic scleroderma diagnosis and efficacy compared to current diagnostics. The test is developed by Medical and Biological Laboratories. In addition, two fatty acid binding protein diagnostics for acute myocardial infarction, developed separately by DS Pharma Biomedical and Biolinks, were priced at ¥1,500. Both diagnostics are able to obtain rapid results compared to current testing. (Click here for more - Japanese language)"Chuikyo Approves Medical Insurance For Three Diagnostics Including Systemic Scleroderma Testing" - Chemical Daily (4/14/2010)
You may also be interested in...
Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.